143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT). (23rd October 2018) - Martin-Liberal, J; Pagliuca, F; Hierro, C; Viaplana, C; Muñoz Couselo, E; Capdevila, J; Matos, I; Fariñas Madrid, L; Zamora, E; Braña Garcia, I; Elez Fernandez, E; Ochoa De Olza Amat, M; et al.